Research using single-cell transcriptomics has found biomarker heterogeneity linked to resistance to CDK4/6 inhibitors in breast cancer cell lines. This discovery is part of a broader exploration of tumor heterogeneity and its role in therapeutic resistance. The study's findings contribute to a larger body of work on the use of single-cell sequencing and multi-omics approaches to better understand cancer biology and improve treatment strategies.